TPCC

Turku Prostate Cancer Consortium

Bringing cancer research together

utu Tyks VSSHP Åbo Akademi Auria

Selected publications

2021

Detection of bladder cancer with aberrantly fucosylated ITGA3. Md. Khirul Islam, Parvez Syed, Bert Dhondt, Kamlesh Gidwani, Kim Pettersson, Urpo Lamminmäki, Janne Leivo. Anal Biochem 2021. Sep 1;628:114283. doi: 10.1016/j.ab.2021.114283.

Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. Uta Erdbrügger, Charles J Blijdorp, Irene V Bijnsdorp, Francesc E Borràs, Dylan Burger, Benedetta Bussolati, James Brian Byrd, Aled Clayton, James W Dear, Juan M Falcón-Pérez, Cristina Grange, Andrew F Hill, Harry Holthöfer, Ewout J Hoorn, Guido Jenster, Connie R Jimenez, Kerstin Junker, John Klein, Mark A Knepper, Erik H Koritzinsky, James M Luther, Metka Lenassi, Janne Leivo, Inge Mertens, Luca Musante, Eline Oeyen, Maija Puhka, Martin E van Royen, Catherine Sánchez, Carolina Soekmadji, Visith Thongboonkerd, Volkert van Steijn, Gerald Verhaegh, Jason P Webber, Kenneth Witwer, Peter S T Yuen, Lei Zheng, Alicia Llorente, Elena S Martens-Uzunova. J Extracell Vesicles. 2021 May;10(7):e12093. doi: 10.1002/jev2.12093.

A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree. Cannon-Albright LA, Teerlink CC, Stevens J, Huang FW, Sipeky C, Schleutker J, Hernandez R, Facelli J, Agarwal N, Trump DL.Cancers (Basel). 15;13(10):2399 2021 doi: 10.3390/cancers13102399.

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Sipeky C, Tammela TLJ, Auvinen A, Schleutker J. Prostate Cancer Prostatic Dis. 2021 May 19. doi: 10.1038/s41391-021-00378-5.

2020

Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. Ecke TH, Kiani A, Schlomm T, Friedersdorff F, Rabien A, Jung K, Kilic E, Boström P, Tervahartiala M, Taimen P, Gleichenhagen J, Johnen G, Brüning T, Koch S, Roggisch J, Wirtz RM. Int J Mol Sci. 21:7420, 2020. doi: 10.3390/ijms21197420.

The interactome of the prostate-specific protein Anoctamin 7. Kaikkonen E, Takala A, Pursiheimo JP, Wahlström G, Schleutker J. Cancer Biomark. 2020;28(1):91-100. doi: 10.3233/CBM-190993.

Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer.Valta M, Ylä-Pelto J, Lan Y, Kähkönen T, Taimen P, Boström PJ, Ettala O, Khan S, Paulin N, Elo LL, Koskinen PJ, Härkönen P, Tuomela J. Transl Androl Urol. 9:1120-1134, 2020. doi: 10.21037/tau.2020.03.38. 

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Ettala O, Malaspina S, Tuokkola T, Luoto P, Löyttyniemi E, Boström PJ, Kemppainen J. Eur J Nucl Med Mol Imaging. 47:665-673, 2020. doi: 10.1007/s00259-019-04635-7.

2019

Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. Khan MFL, Soikkeli M, Routila E, Krannila S, Terävä J, Taimen P, Boström PJ, Pettersson K. J Appl Lab Med, 2019. doi: 10.1373/jalm.2018.027797. 

ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. Kaikkonen E, Ettala O, Nikulainen I, Taimen P, Lehtinen I, Boström PJ, Kellokumpu-Lehtinen PL, Schleutker J. Anticancer Res, 39:5353-59, 2019. doi: 10.21873/anticanres.13728.

Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. Anttinen M, Yli-Pietilä E, Suomi V, Mäkelä P, Sainio T, Saunavaara J, Eklund L, Blanco Sequeiros R, Taimen P, Boström PJ. Int J Hyperthermia. 36:915-925, 2019. doi: 10.1080/02656736.2019.1652773. 

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P. European Urology 76,430-4, 2019. doi: 10.1016/j.eururo.2019.06.016.

IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. Merisaari H, Jambor I, Ettala O, Boström PJ, Montoya Perez I, Verho J, Kiviniemi A, Syvänen K, Kähkönen E, Eklund L, Pahikkala T, Vainio P, Saunavaara J, Aronen HJ, Taimen P. J Magn Reson Imaging, 50:1641-50, 2019. doi: 10.1002/jmri.26727.

Cell-type specific CD73 expression is an independent prognostic factor in bladder cancer. Koivisto M, Tervahartiala M, Kenessey I, Jalkanen S, Boström PJ, Salmi M. Carcinogenesis 12:40:84-92, 2019. doi: 10.1093/carcin/bgy154. 

2018

Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. Knuuttila M, Mehmood A, Mäki-Jouppila J, Ryberg H, Taimen P, Knaapila J, Ettala O, Boström PJ, Ohlsson C, Venäläinen MS, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M. Endocrine Related Cancer 25:807-819, 2018. doi: 10.1530/ERC-18-0148.

Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer. Sipeky C, Gao P, Zhang Q, Wang L, Ettala O, Talala KM, Tammela TLJ, Auvinen A, Wiklund F, Wei GH, Schleutker J. Clin Cancer Res. 15;24(24):6265-6276, 2018 doi: 10.1158/1078-0432.CCR-18-0444.

ANO7 is associated with aggressive prostate cancer. Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J. Int J Cancer 15:2479-2487, 2018. doi: 10.1002/ijc.31746.

The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis. Ojalill M, Rappu P, Siljamäki E, Taimen P, Boström P, Heino J.Prostate. 78:583-594, 2018. doi: 10.1002/pros.23503.

New prostate cancer grade grouping system predicts survival after radical prostatectomy. Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.Hum Pathol. 75:159-166, 2018. doi: 10.1016/j.humpath.2018.01.027.

2017

Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. Tervahartiala M, Taimen P, Mirtti T, Koskinen I, Ecke T, Jalkanen S, Boström PJ. Scientific Reports. 2017 7:12682, 2017. doi: 10.1038/s41598-017-12892-5. 

2016

Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M.PLoS One 11(5):e0155901, 2016. doi: 10.1371/journal.pone.0155901.

Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. Alinezhad S, Väänänen RM, Ochoa NT, Vertosick EA, Bjartell A, Boström PJ, Taimen P, Pettersson K.BMC Urol. 16(10), 2016. doi: 10.1186/s12894-016-0128-8. 

Increased expression of fibroblast growth factor 13 (FGF13) in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P.Int J Cancer, 139:140-52, 2016. doi: 10.1002/ijc.30048.

Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. Alinezhad S, Väänänen RM, Tallgrén T, Perez IM, Jambor I, Aronen H, Kähkönen E, Ettala O, Syvänen K, Nees M, Kallajoki M, Taimen P, Boström PJ, Pettersson K.Urol Oncol. 34:255.e15-22, 2016. doi: 10.1016/j.urolonc.2015.12.014.   

2015

Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. Väänänen RM, Ochoa NT, Boström PJ, Taimen P, Pettersson K.BMC Urol 15:88, 2015. doi: 10.1186/s12894-015-0077-7. 

Tumor associated macrophages provide significant prognostic information in urothelial bladder cancer.Boström MM, Irjala H, Mirtti T, Taimen P, Kauko T, Ålgars A, Jalkanen S, Boström PJ.Plos One 10;e133552, 2015. doi: 10.1371/journal.pone.0133552.